Supplier
San Diego Oncology Medical Clinic
San Diego Oncology Medical Clinic was paid $6.26M by Medicaid between Jan 2018 and Dec 2024, across 51 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 19% of everything it billed.
33Billing provider infoSAN DIEGO ONCOLOGY MEDICAL CLINIC
SAN DIEGO, CA 92123
SAN DIEGO, CA 92123
33aNPI1871844522assigned 09/20/2012
33bProvider typeNon-Pharmacy Dispensing Site
28Total paid$6.26M
24GClaims176,443
24DCodes billed51
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Non-Pharmacy Dispensing Site providers in California
Rank by total paid#6 of 22
Median peer was paid$112K
This provider vs. median56×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,598 | $1.05M | |
| 2019 | 27,833 | $887K | |
| 2020 | 26,872 | $900K | |
| 2021 | 28,413 | $1.21M | |
| 2022 | 28,392 | $1.04M | |
| 2023 | 29,213 | $912K | |
| 2024incomplete | 11,122 | $261K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 19% | 22,101 | 14,092 | $1.16M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14% | 14,743 | 11,377 | $845K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 10% | 8,318 | 4,666 | $652K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 7.2% | 1,871 | 1,090 | $452K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 7.0% | 3,752 | 1,879 | $440K |
| 96411 | 5.1% | 5,224 | 2,908 | $321K | |
| J9271 | Injection, pembrolizumab, 1 mg | 4.7% | 57 | 40 | $297K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 4.7% | 3,383 | 1,571 | $296K |
| 36593 | 4.7% | 13,167 | 7,925 | $293K | |
| 96417 | 3.6% | 3,233 | 2,147 | $224K | |
| 96415 | 3.3% | 4,541 | 2,708 | $206K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.9% | 3,318 | 1,970 | $179K |
39 more codes
| 99215 | Doctor's office visit, returning patient (complex) | 2.2% | 1,578 | $135K |
| 99223 | Prolong inpt eval add15 m | 1.8% | 1,159 | $116K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 31,071 | $99K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 1.5% | 56 | $93K |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 1.2% | 6,682 | $75K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 1.0% | 218 | $65K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,634 | $56K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,216 | $38K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,266 | $29K |
| 96401 | <1% | 1,058 | $24K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,884 | $21K |
| 82950 | <1% | 9,121 | $18K | |
| 99000 | <1% | 4,881 | $17K | |
| J9171 | Injection, docetaxel, 1 mg | <1% | 26 | $14K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,621 | $12K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,513 | $9K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,641 | $9K |
| 99205 | Prolong outpt/office vis | <1% | 63 | $9K |
| 99245 | <1% | 90 | $9K | |
| 90686 | <1% | 677 | $8K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 159 | $8K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 153 | $5K |
| 90670 | <1% | 56 | $5K | |
| 90732 | <1% | 59 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 138 | $2K |
| 90677 | <1% | 12 | $2K | |
| 96367 | <1% | 37 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,430 | $1K |
| 85610 | <1% | 596 | $1K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 29 | $682.15 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 315 | $645.68 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 38 | $615.86 |
| 90756 | <1% | 69 | $557.07 | |
| 99406 | <1% | 44 | $492.26 | |
| 90658 | <1% | 18 | $317.03 | |
| 90656 | <1% | 19 | $98.69 | |
| Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | <1% | 17 | $87.05 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 27 | $34.41 |
| G0008 | Administration of influenza virus vaccine | 0% | 64 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSONG, SEUNG-YIL (MD)